When no means yes.

Writing in the Australian Financial Review Shareholders May Sink Cellestis Deal Andrew Lau remarked that

Qiagen would not comment but its spokesperson said that several brokers had noted that the acquisition price was expensive given that it was about 8.5 times Cellestis’ 12-month trailing revenue, although that may not be a fair comparison due to the target’s low market penetration.

Is that or is that not a comment?